|Day Low/High||75.96 / 77.35|
|52 Wk Low/High||72.30 / 92.39|
A look at Amgen's dispute with Novartis as well as Lam Research stock.
Mayzent tablets to treat relapsing multiple sclerosis have been approved by the FDA. But the treatment comes with a hefty price tag.
Plus, why investors should care about the yield curve, and a closer look at Tilray's quarter.
Tilray will not be cash flow positive for another 2-3 years - that's not quick enough progress for me given its $7 billion dollar capitalization.
The move was helped by the TLRY's deals with AB InBev for beverages and Novartis for medical applications.
If we can advance without China then who the heck knows where we can go with it.
Spark Therapeutics shares more than double Monday after the gene therapy specialist agreed to a $4.3 billion takeover by Switzerland-based Roche Holding, the world's biggest maker of cancer treatments.
Medicine is a slow business and I view Gilead Sciences as a hold for now.
CBD could make coffee an around the clock craze.
Big pharma is shaping up to be a consolidating category in 2019.
One of pharma's biggest CEO's talks M&A action on the exchange.
This will be the craziest reporting season we've seen in ages, says Jim Cramer. He's got your game plan for next week.
Canopy Growth's smoking engine won't necessarily ensure smooth sailing for Constellation.
The stock's performance has been impressive in the past three months.
Jim Cramer says companies that innovate become market-leading stocks, and can create tremendous wealth.
We're out in San Francisco this week covering the amazing innovations that so many companies reveal at this annual conference.
Legal-marijuana firm surges on deal with Budweiser parent AB InBev to develop cannabis-based drinks.
I'd be most interested in buying this name after a cap raise which I expect in the first quarter of 2019.
Pot stock partnerships are a gateway to gains for cannabis investors.
Some ancillary help came trickling through the door Tuesday, with possibly more on the way.
Canadian cannabis producer's stock jumps on announcement that it's teaming up with Novartis's Sandoz until to sell and distribute medical cannabis products globally.
Tilray will have a lot to tackle this evening.
- Additional analysis from pivotal Phase III SOLAR-1 clinical trial studying investigational alpha-specific PI3K inhibitor BYL719 (alpelisib) and fulvestrant in patients with PIK3CA-mutated HR+/HER2- advanced or metastatic breast cancer
Small and mid-cap biotech firms are driving innovation in the sector. Experts explain why investors should take notice.
Stocks fall sharply on Thursday after a hawkish set of minutes from last month's Federal Reserve meeting cements the case for near-term interest rate hikes.
The Swiss drugmaker will pay $2.1 billion for Endocyte, justifying the Nasdaq-listed biotech's pivot to prostate treatment last year.
It's time for the central bank to show the same level of concern for their misplaced aggression.
U.S. stock futures decline after a hawkish set of minutes from last month's Federal Reserve meeting; American Express, PayPal and Travelers report earnings; Facebook believes hack was done by spammers, says a report; Novartis to buy Endocyte for $2.1 billion.
TheStreet’s Fundamentals of Investing Course will teach you the keys to making the right decisions in any market.
TheStreet’s Personal Finance Essentials Course will teach you money management basics and investing strategies to help you avoid major financial pitfalls.
TheStreet Courses offers dedicated classes designed to improve your investing skills, stock market knowledge and money management capabilities.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.